Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Telix Pharmaceuticals submits BLA for kidney cancer imaging agent TLX250-CDx (Zircaix) based on Phase III ZIRCON study.

16 months ago
4 Articles

Further Reading